---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-22-035788"
form_type: "8-K/A"
ticker: "ZVSA"
cik: "0001859007"
company_name: "ZyVersa Therapeutics, Inc."
filed_at: "2022-12-16T23:59:59+00:00"
generated_at: "2026-06-21T03:40:51.884755+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# ZyVersa reports Q3 2022 net loss of $3.7M, R&D spend up 473% YoY

## Summary
- Net loss of $3.693M for Q3 2022 vs $1.879M in Q3 2021; nine-month loss $9.445M.
- R&D expenses surged to $2.334M in Q3 2022 from $0.407M, driven by $1.928M in IC100 drug manufacturing.
- Cash used in operations improved to $1.078M for nine months 2022 from $4.460M in 2021.
- Financing provided $1.353M via preferred stock private placement; no revenue disclosed.

## SEC filing metadata
- accession: 0001493152-22-035788
- form_type: 8-K/A
- ticker: ZVSA
- cik: 0001859007
- company_name: ZyVersa Therapeutics, Inc.
- filed_at: 2022-12-16T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1859007/000149315222035788/0001493152-22-035788-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1859007/000149315222035788/form8-ka.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-22-035788
- JSON: https://secwatch.observer/filing/0001493152-22-035788.json
- Plain text: https://secwatch.observer/filing/0001493152-22-035788.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.